Stock IVX INVION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Invion Limited

Equities

IVX

AU000000IVX4

Biotechnology & Medical Research

Delayed Australian S.E.
Other stock markets
 10:20:32 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.006 AUD 0.00% Intraday chart for Invion Limited 0.00% +20.00%
Mar. 05 Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results MT
Feb. 27 Invion Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 186.7 82.51 44 72.01 57.75 25.69
Enterprise Value (EV) 1 183.9 81.74 43.39 70.98 49.28 21.6
P/E ratio -26.6 x -65.2 x -40.2 x -43.5 x -22.6 x -13.4 x
Yield - - - - - -
Capitalization / Revenue 253 x 21.3 x 12.7 x 30.9 x 17.5 x 6.26 x
EV / Revenue 249 x 21.1 x 12.5 x 30.5 x 15 x 5.26 x
EV / EBITDA -198 x -37 x -58 x -54.8 x -27.1 x -22.4 x
EV / FCF 185 x -75.8 x 268 x 72.5 x -6.54 x -5.59 x
FCF Yield 0.54% -1.32% 0.37% 1.38% -15.3% -17.9%
Price to Book 23.6 x 15.1 x 8.11 x 15 x 2.95 x 1.4 x
Nbr of stocks (in thousands) 5,492,273 5,500,606 5,500,606 5,539,542 6,416,514 6,421,632
Reference price 2 0.0340 0.0150 0.008000 0.0130 0.009000 0.004000
Announcement Date 8/28/18 8/28/19 8/26/20 8/4/21 8/17/22 9/28/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 0.7377 3.882 3.477 2.33 3.292 4.105
EBITDA 1 -0.9265 -2.208 -0.7486 -1.294 -1.819 -0.9654
EBIT 1 -2.252 -2.517 -1.026 -1.572 -2.241 -1.648
Operating Margin -305.21% -64.85% -29.52% -67.48% -68.09% -40.16%
Earnings before Tax (EBT) 1 -4.218 -2.546 -0.9539 -1.483 -2.241 -1.615
Net income 1 -4.87 -1.064 -0.9539 -1.483 -2.241 -1.615
Net margin -660.17% -27.41% -27.44% -63.65% -68.09% -39.34%
EPS 2 -0.001276 -0.000230 -0.000199 -0.000299 -0.000399 -0.000299
Free Cash Flow 1 0.9931 -1.078 0.1619 0.9792 -7.539 -3.865
FCF margin 134.61% -27.76% 4.66% 42.03% -229.03% -94.16%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 8/28/18 8/28/19 8/26/20 8/4/21 8/17/22 9/28/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2.87 0.77 0.62 1.04 8.47 4.08
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.99 -1.08 0.16 0.98 -7.54 -3.86
ROE (net income / shareholders' equity) -81.8% -38.1% -17.5% -29% -18.4% -8.5%
ROA (Net income/ Total Assets) -17.4% -19.2% -10.9% -17.2% -10.9% -5.27%
Assets 1 27.96 5.55 8.79 8.604 20.55 30.63
Book Value Per Share 2 0 0 0 0 0 0
Cash Flow per Share 2 0 0 0 0 0 0
Capex - 0.01 - - - 0.08
Capex / Sales - 0.16% - - - 1.85%
Announcement Date 8/28/18 8/28/19 8/26/20 8/4/21 8/17/22 9/28/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
INVION LIMITED Stock Invion Limited
+20.00% 25.14M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. IVX Stock
  4. Financials Invion Limited